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Structured abstract (184 words) 
 
Introduction 
Despite a burgeoning knowledge of the intricacies and mechanisms responsible for human 
disease, technological advances in medicinal chemistry, and more efficient assays used for 
drug screening, it remains difficult to discover novel and effective pharmacologic therapies.   
 
Areas covered 
By reference to the primary literature and concepts emerging from academic and industrial 
drug screening landscapes, we propose that this disconnect arises from the inability to scale 
and integrate responses from simpler model systems to outcomes from more complex and 
human-based biological systems.  
 
Expert opinion 
Further collaborative efforts combining target-based and phenotypic-based screening along 
with systems-based pharmacology and informatics will be necessary to harness the 
technological breakthroughs of today to derive the novel drug candidates of tomorrow. New 
questions must be asked of enabling technologies- whilst recognising inherent limitations- in a 
way that moves drug development forward. Attempts to integrate mechanistic and 
observational information acquired across multiple scales frequently exposes the gap between 
our knowledge and our understanding as the level of complexity increases. Here we offer our 
thoughts and some actionable items that we hope will inform directed evolution of the drug 
discovery process.  
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“Disease is not something personal and special, but only a manifestation of life under modified 
conditions, operating according to the same laws as apply to the living body at all times, from 
the first moment until death”.    Rudolf Virchow (Die Epidemien von 1848, 7) 
 
1. Introduction to complexity as the missing link in drug discovery 
Technological innovations and advances continue to provide more detailed and refined 
mechanistic information on diseases targeted for novel pharmacologic therapies.  There has 
been an explosion in approaches using human cell systems with disease-relevant genotypes 
and phenotypes (e.g. organ-on-a-chip, stem-cell derived models), advances in chemistry, new 
automated platforms for high-throughput, high-content screening, numerous ‘omics’ 
approaches, and advanced computational tools for visualising and deep-mining data to provide 
data regarding effects of novel drug candidates [1, 2].  Many of these advances provide 
enhanced tools for re-running ‘traditional assays in new formats, and thus allow us to take full 
advantage of screening vast compound libraries to derive tomorrow’s new drugs.  However, we 
are essentially asking the same questions of these platforms and as a result we continue to 
identify compounds that, more often than not, fail to translate into clinical utility. So far, we have 
failed to utilize these new technologies in truly transformative ways along the drug development 
process.   
 Part of the problem stems from the use of simpler model systems in which the outputs 
are easier to interpret and which themselves are more amenable to higher throughput 
screening approaches but which offer only restricted insights into the disease-causing process 
and/or the real mechanisms of drug effect.  There is still much regarding the multiple levels of 
organization and complexity in biology and disease that we do not understand.  Consider the 
use of stem cell-derived systems (e.g. embryonic- and induced pluripotent stem cell-derived 
cardiomyocytes and hepatocytes) increasingly being used in drug discovery.  The opinion that 
they are not the panacea for efficacy or safety studies may be true but they do offer some 
obvious advantages over non-human equivalents and represent a pragmatic choice of cell 
platform for studying “disease-in-a-dish” [3, 4, 5].  However, no cell model fully recapitulates all 
facets of the biology that occurs in vivo (hence the term “models), and it is legitimate to 
question whether such assays are “fit for purpose”.  Furthermore, data acquired from these 
preparations may be prone to misinterpretation if the limitations inherent in the models are not 
considered (see [6] for a specific example relating to the absence in stem-cell derived 
cardiomyocytes of a K+ channel that is critical in establishing human resting membrane 
potential (IK1)).  Whilst substantial efforts and resources are directed at modifying such cell 
preparations in order to mimic their behaviour in tissues in vivo, still many extrinsic factors that 
shape proper cellular form and function are missing from current experimental setups. The 
precise configurations of heterocellularity and interconnectedness, regional variability within 
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tissues, mechanical tensions, electrical and hormonal cues, nutrient availability and localised 
redox environments that may change dynamically in vivo- and which influence steady-state 
behaviour and biological responsiveness- are extremely difficult to recreate in vitro.  Such 
considerations have shifted the discussion from “how relevant is that mouse study to human 
findings” to “how relevant are human cell-derived model studies to human findings”.  
 It seems that in our efforts to understand the reasons behind the technical inadequacies 
of contemporary experimental platforms used in drug discovery we are fundamentally failing to 
grasp less tangible aspects that are intimately involved in shaping biological behaviour and 
responsivity.  What are those elements that evade easy quantification and which provide 
missing links enabling us to better translate “data richness” into improved clinical therapies?  
Here, we present the case that a key link presently missing- and one that is pivotal in moving 
drug development forward from preclinical models (using non-human cells) to ‘proclinical’ 
models (using human-derived cells in preclinical studies) and from there to clinical utility - is 
complexity.   
 We are not suggesting that drug hunters do not understand or appreciate the intricate 
complexities involved in normal physiology or diseased states [7].  In this this review, we posit 
that experimental tools and approaches used to probe complex human systems are imperfect 
and incomplete and as a consequence give rise to outputs that are difficult to properly 
synthesise and interpret. In section 2, we illustrate, with reference to examples, the requirement 
for integrating data from multiple models characterised by different levels of complexity. Section 
3 distils our thoughts on some of the factors that influence the ability to properly interrogate the 
component model systems that are used in building more complex systems. Lastly, Section 4 
briefly describes the need to consider the ‘physiologic gamut’ in order to appropriately 
contextualise biological range and complexity.  
 
 
2. The need for multiple models of different complexity  
Figure 1 depicts a schematised framework of “quantitative and systems pharmacology” (QSP) 
that integrates information emerging at multiple scales using the idea of ‘horizontal’ and 
‘vertical’ network architecture [8, 9].  Erwin Chargaff’s prediction in the context of genetic 
engineering that “If you can modify a cell, it’s only a short step to modifying a mouse, and if you 
can modify a mouse, it’s only a step to modifying a higher animal, even man” [10] may hold true 
conceptually, but it does not fully recognize the nature of all of the components- some 
quantifiable, some not- involved in ‘scaling up’.  There is an essential need to understand the 
basis of the increased complexity associated with transitions from the molecular scale through 
to organisms and beyond that reflects the fidelity of translation to the clinic; such transitions are 
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chasms, not short steps and not unlike the “Valley of Death” phrase used to describe the 
arduous transition of drugs from laboratory findings to successful human clinical trials. 
The tension created by considering how best to integrate information acquired at 
different scales of complexity is mirrored in the general approaches used to screen for new 
drugs. Swinney and Anthony’s review highlights the need to make two essential elements of 
the drug development toolkit work together in a more meaningful way to guide drug discovery 
efforts [11].  The first approach, labelled mechanistic- or target-based screening (TBS), usually 
involves the detailed characterization of lower-order complexity systems (e.g. molecule or 
signalling node) to resolve distinct molecular mechanism of action (MMOA).  The second 
approach, labelled phenotypic screening (PS), is defined by Swinney and Anthony as “all 
modes of assays in which a biological system (and the perturbation therein) can be faithfully 
recapitulated”.  PS seeks to quantify measurable changes in the behaviour of more complex 
systems in the absence of knowledge of the MMOA and thus describes empirical methods to 
evaluate integrated responses of biological systems of varying complexity (for example, 
pathways, cells, tissues, animals).  Arguably, PS has played a major role in discovering 
therapeutics with novel mechanisms of action (so-called first in class drugs) [11, 12]. Such 
successes have been attributed (at least in part) to preservation of systems complexity in 
experimental models and the ability to monitor relevant (and often integrated) endpoints. It 
could also be argued that PS involves more serendipity; others have offered views on how this 
might be systematized [13]. 
 In general, most drug discovery efforts are enabled by a newly-recognized 
understanding of a mechanism or pathway that plays a putative key role in a complex disease. 
For example, it is expected that by modifying a key receptor, enzyme, metabolic pathway, 
signaling cascade or expressed protein that disease progression is favorably altered or 
reversed. This ‘target-centric’ approach allows for a linear progression of stage gates that 
govern a wide range of discovery efforts that include lead identification and optimization, 
preclinical efficacy and safety testing, pharmacokinetic modeling and formulation, and early 
phase 1 (first in human) studies leading to subsequent pivotal clinical trials to test for efficacy.  
This strategy is most likely to succeed if the targeted mechanism a) plays a unique role in 
human disease progression b) is well understood within cellular, organ, and organism contexts, 
and c) if either more simplified models (including in silico, in vitro, ex vivo) and more complex 
models (including animal models) are available that faithfully recapitulate the disease or events 
leading to the disease.  The possible contribution of multiple on-target effects involving less 
recognized (or unknown) pathways to the overall efficacy of novel therapeutics may further 
complicate an understanding of a drug’s efficacy.  Further, a drug’s off-target (or side-effects) 
profile at exposures comparable to those defining efficacy may also confound understanding 
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drug efficacy.  It is more likely that phenotypic effects would detect off-target effects (as 
compared to TBS focused on MMOA).   
Unfortunately, most (if not all) of the three assumptions listed above are only partially 
fulfilled; if we knew everything about the disease, it would be much simpler to design and 
discovery appropriate chemistries from an ever-expanding list of approaches (spanning small 
molecules and biologics to delivered gene therapies) to affect pharmacologic endpoints.  For 
practical reasons that include speed, efficiency, cost, and clarity of interpretation, simpler model 
systems are generally used (and favored) for screening of chemical libraries in early discovery 
efforts.  If available, more complex models may be employed later in drug discovery to more 
fully evaluate efficacy (if such disease models exist) and safety (using non-diseased models).  
Absent of such models, biomarkers may be used as surrogate markers for efficacy, informing 
on target engagement.  These same biomarkers may also be used in early human studies to 
again test for target engagement, an essential first step in validating a therapeutic target in 
clinical studies. 
More recently, PS have been applied to safety studies using humanized models (e.g. 
human induced pluripotent stem cell-derived cardiomyocytes and hepatocytes [4, 5]), with the 
potential advantage that the human-derived biology under study more closely represents the 
clinical experience.  Patient-derived stem cell-based in vitro models (for either safety or efficacy 
studies) have also been described in which simpler human derived cells, or more complex co-
cultures, and organoids are used.  A major question for these “disease in a dish” studies is the 
extent to which the disease phenotype is faithfully (and reproducibly) replicated.  This is more 
likely to be achieved with monogenic inheritable diseases than with diseases resulting from 
multiple genetic and environmental influences.  More recent gene-editing tools provided by the 
discovery of CRISPR-Cas techniques hold promise for creating more complex humanized in 
vitro disease models provided that we understand better the underlying disease mechanisms.  
Of course, a fusion of both target- and phenotypic-directed experimental approaches can be 
used, depending on the understanding of the complex biology and our ability to recreate and 
monitor complex biological responses.   
A principle feature of PS is that the approach affords unbiased assessments of 
compound activity on a pre-defined aspect of system behaviour (e.g. reduced incidence of 
seizure or episodes of arrhythmia).  However, one of the drawbacks of PS is that because the 
assays are often necessarily more observational in nature, teasing out the underlying 
mechanism(s) may be difficult and prone to flawed interpretation.  The very nature of PS 
means that: 
 1) since any change likely involves networks and interactions between numerous components, 
the measured outcome may not be directly related to modulation of the presumed molecular 
target and 
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 2) any outcome may not be predictable from an understanding of the individual components 
involved (i.e. emergent behaviour).  
Such features can cause issues when retrospectively fitting mechanism (i.e. MMOA) to the 
phenomenological effects observed (i.e. the apparent MOA) in more complex systems.  From a 
more pragmatic perspective, detailed knowledge on the MMOA may be unnecessary when 
screening drug candidates. 
 To illustrate the difficulties in reverse-engineering data obtained from higher complexity 
systems, we consider the histories of three clinically used cardiovascular drugs.  Investigations 
on ranolazine and perhexiline, drugs that were originally developed as anti-anginal agents 
based on a blueprint of synthetic blockers of voltage-gated ion channels in the cardiovascular 
system [14], were founded on a presumed mechanism of action that involved direct alterations 
in metabolic substrate utilization [15, 16]. The endpoints of these clinical studies demonstrated 
the therapeutic benefit of the drugs under test and the data acquired from NMR on substrate 
utilization in situ was compatible with a mode of drug action on cellular metabolism.  However, 
in vitro studies in lower complexity systems revealed that the MMOA of ranolazine and 
perhexiline (with clinically relevant exposures) most likely occurred through voltage, frequency 
and tissue-dependent block of multiple ion channels involved in cardiovascular homeostasis 
[14, 17, 18]. Any effect on metabolism would be secondary to the inhibition of these ion 
channels.  We draw particular attention to perhexiline since its serves to highlight the potential 
for ascribing clinical efficacy to uncertain MMOA if ‘single mode’ assessments are considered 
in isolation from data obtained from other experimental platforms.  Any action of perhexiline on 
cellular metabolism (i.e. potent inhibition of carnitine palmitoyl transferase (CPT-1) [16]) was 
informed by investigations using an in vitro biochemical assay of CPT-1 inhibition in rat liver 
and heart homogenates [19].  Outputs from this assay cannot resolve the contribution of the 
drug’s interaction with other (more well-known) targets in vivo (e.g. ion channels) and extensive 
scrutiny from a medicinal chemistry perspective concluded that the clinical efficacy of this drug 
is unlikely to be primarily related to an inhibitory action on CPT-1 activity [14, 20].  In another 
example of the potential disconnection between therapeutic benefit and presumed MMOA, 
investigations on flecainide, a class Ic (Na+ channel blocking) anti-arrhythmic that is highly 
effective in the clinical management of genetic and idiopathic arrhythmia syndromes [21, 22], 
have produced data that prevent the unequivocal assignation of its MMOA [23, 24, 25]. To 
reconcile discrepant findings, a ‘triple mode’ mechanism of flecainide action has been proposed 
that considers direct and indirect effects of the drug on multiple targets (Na+ channel, 
sodium/calcium exchanger and ryanodine receptors) [26, 27, 28]. However, the harmonization 
of experimental data to fit to a ‘unifying’ MOA of flecainide has been precluded by findings from 
single molecule studies (i.e. an exemplar TBS) that contradict any direct effect on ryanodine 
receptors [29, 30, 31]. This narrative serves to emphasise the potential utility of lower-
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complexity systems to specifically resolve the nature of drug-target interactions.  These 
examples highlight the contributions of naming and identifying specific “on-target” actions 
without considering the full universe of possible drug effects either on individual key cellular 
components, or the consequences of such interactions across multiple networks and systems 
within and beyond cells (Figure 1).  
 The above examples attest to the difficulty of resolving MMOA from studies using more 
complex systems but also reveal the potential for being unable to delineate between ‘cause 
and effect’ by using systems of reduced complexity, especially if the data is considered in 
isolation from those emerging from complementary approaches.  To this end, there is much 
that can be learned from considering biology using the same principles of interdependency and 
interconnectedness that are inherent in other network structures.  We expand on this in 
sections 3 and 4, below.  The situation with biology (as compared to engineering with 
mathematical models, for example) is rendered more difficult by practical limitations; the 
success of resolving MMOA from rather observational effects is largely dependent on the 
availability of good quality reagents to probe the underlying biology (e.g. antibodies, specific 
antagonists etc.) and an understanding the networks involved.  New approaches that 
decompose complexity show promise in resolving the direct or consequential actions of a 
compound on the observed changes [32] and should help mitigate errors of interpretive bias in 
data emerging from complex platforms.  
 Although we focus on the need to consider complexity (mindful of the problems 
associated with doing so), we are not advocating an “anti-reductionist” agenda.  After all, the 
study of very low complexity systems (e.g. flecainide interaction with single ryanodine receptors 
[29, 30, 31]) is required to unequivocally resolve fundamental mechanisms of drug-protein 
interaction separate from any confounding complexity (i.e. the true MMOA).  Thus, TBS and PS 
are not ‘either-or’ options and there is an absolute need for the appropriate placement of TBS 
in the development pathway.  However, the connection between TBS and PS cannot be viewed 
as a ‘linear’ link in which one approach naturally follows the other; the deployment of these 
approaches should be matched to a given phase of the development pipeline and that the level 
of complexity is tractable and fit for purpose.  There is likely to be a need to revisit the approach 
again once one is armed with more knowledge gained from studies on models of different 
complexity.  We propose therefore to define a ‘next generation’ of screening frameworks thus: 
“complementary assays performed on systems of sufficient complexity that can resolve the 
contribution of discrete components to mechanism of action in vivo”.  Such capability will 
inevitably involve computational biology and require informatics support [33].  We consider 
these issues and other features of future frameworks that will be needed to fulfil these criteria in 
sections 3 and 4. 
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3. Exploring dynamical changes in system deterioration  
The ultimate goal of pre-clinical assays is to accurately predict a drug’s clinical therapeutic 
efficacy and safety.  As Swinney notes, “the more relevant the system is to physiology, the 
better it will predict the clinical success” [12].  The use of the term ‘physiology’ here is key; 
physiology represents the functional coalescence of interlocking biological processes in a 
network architecture that involves the multi-layering of components (Figures 2 and 3).  In this 
context, the prediction of outcome in response to a given drug treatment or pathological 
disruption is difficult since the network gives rise to a number of characteristics that define the 
non-linear behaviour of the linked processes (e.g. entrainment, emergence, resilience, 
robustness, fragility) [34, 35, 36, 37, 38, 39, 40, 41, 42].  It is not practically possible at present 
to take into account and measure all of the variables and connections that contribute to such 
system non-linearity.  In Figure 2, we use the example of β-AR signalling to illustrate a process 
where the output (i.e. downstream phosphorylation of multiple proteins) is dependent on 
multiple network connections.  Figure 3 depicts how the release of Ca2+ from the sarcoplasmic 
reticulum (SR) through intracellular Ca2+ release channels (ryanodine receptors) is enmeshed 
in the process of excitation-contraction coupling (ECC) [43] which is regulated by the alignment 
of ‘horizontal’ and ‘vertical’ network elements.  We return to the issue of network alignment in 
section 4. 
 In terms of attempting to untangle these networks in order to establish cause and effect, 
Verspignani paints a rather nihilistic picture of “complex systems for which it is generally 
impossible to abstract the global behaviour from the analysis of single components, especially 
under conditions of failure [and disaster]” [42].  One of the more paradoxical aspects of 
physiological complexity is that it is underpinned by the use of comparatively few core 
components.  Akin to a chef producing an array of food dishes from few key ingredients, 
complexity stems from differential configurations of macromolecular nodes, signalling modules 
and functional outputs [44, 45, 46, 47].  Given the network constraints imposed on the 
functionality of each of these interlocked components therefore, it is important to recognize that 
a fundamental limitation of those studies that model change (e.g. drug-induced toxicity) in more 
complex physiological systems where redundancy of components is also a key characteristic is 
that the most critical linkages between components are those that cannot change if the system 
is to remain operational.  Under these circumstances any measureable change may only 
directly reflect the consequential system adaptation and only indirectly the primary causal 
perturbation.  
 The notion that signalling components (e.g. G-protein coupled receptors) exist in 
different physical/functional states in normal and diseased states gives credence to those 
approaches that aim to assess drug effects only in the diseased state [11].  It is widely 
Gintant & George 
Harnessing complexity in drug development 
	 10 
appreciated that drugs developed using ‘normal’ models may fail to produce anticipated 
outcomes in the diseased state.  Whilst it is clear from our arguments above that it is difficult to 
develop experimental systems that mimic faithfully such disease-linked reconfigurations in such 
a way that we can fully understand the model outputs, there is presently huge efforts focussed 
on biased agonism of cell-surface receptors and in engineering functional receptor selectivity in 
drug binding studies [48].  Finally, it is essential to conduct preclinical studies in non-diseased 
models, as most drugs (cytotoxic oncology drugs being the major exception) are administered 
to normal individuals in early clinical safety studies (before putting patients at risk), and (absent 
personalized medicine) patients without the disease indication will likely encounter these drugs 
in clinical settings. 
 Extending the concepts above, it is necessary to consider the dynamic component of 
pathological processes and disease.  It is legitimate to question the relevance of relatively static 
assay modalities.  Indeed, one would likely expect different responses treating patients with 
different severity of disease in different settings (as well as different comorbidities).  Performing 
investigations in experimental systems that recreate some endpoint of disease fits with the 
concept of drugging the diseased state.  However, it would be advantageous to have 
preventative therapeutics to influence disease progression.  It is informative to consider this 
process as involving multiple transitions from a normal state through intermediate stages 
(termed “adaptive decline”19,35) into an abnormal (final) state.  According to this concept, the 
very early stages of disease are associated with changes in biological function that may not 
give rise to measureable alterations in a chosen model of disease.  Figure 4 considers this 
issue by depicting the inherent disequilibrium in the observable ‘steady states’ as the normal 
scenario becomes abnormal.  To illustrate this concept within the constraints of the present 
article, we have restricted our focus to the maladaptive ‘decline’ of a biological system i.e. the 
concept of disease progression as the manifestation of reduced complexity.  This view is 
corroborated by models of cellular and organ dysfunction [49, 50] but we should point out that 
the progression of some diseases (e.g. cancer) are associated with an increased tissue 
complexity (if one were to take the augmented degree of tumor heterogeneity as an index of 
complexity), unpredictable disease behavior, and reduced efficacy of therapy [7]. 
Figure 5 highlights how it is possible to configure assays (including the appreciation of 
the importance of frequent sampling) to probe and quantify changes in dynamic experimental 
systems that distinguish mechanisms of drug action.  Similar concepts may be applied towards 
understanding the increasing risk liabilities involved when considering the safety of novel drugs, 
which often involves multiple factors which together define overall safety.  The application of 
gene-engineering approaches should provide the ability to induce genetically-derived disease 
progression models to use for assessing a drugs’ effects on altered networks linked with 
disease progression.  Perhaps in the future the idea of drugging an established diseased state 
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will be considered as outdated, instead being replaced by pro-active, preventative regimes, 
based on an improved knowledge on the dynamics of disease progression.  
 A note about the configuration of components within networks.  The interaction of 
‘nodes’ and ‘hubs’ in a network is not endlessly configurable nor is the functionality of individual 
components.  By way of example, previous estimations have shown that, in principle, 
phosphorylation of a single (tetrameric) ryanodine receptor by CaMKII, if each monomer has up 
to eight independent CaMKII phosphorylation sites, could result in around 1010 different states 
[51].  It is not plausible that the vast majority of these configurations will exist in situ, nor that 
there will be a discrete functional response to the few phosphorylated configurations that will be 
achieved if phosphorylation represents a simple ‘on-off’ biological switch to regulate 
downstream targets. Networks constrain the function of key nodes to tolerable configurations 
that dictate how a particular system can behave.  We consider this in more detail in section 4. 
 
 
4. Defining the physiological gamut and systems limits.  
In section 3, we outlined some of the issues relating to the development of assays that can 
resolve the dynamic nature of pathogenesis.  Based on this, one might reasonably argue that 
we are at - or indeed, have already surpassed- the point of our ability to use simpler in vitro 
experimental systems to advance further our efforts to discover novel mechanism-based 
therapeutics.  Maybe we are now in a phase of diminishing returns?  Returning to the problems 
discussed in section 2 about bridging ‘scale’, complex interactions between the layers of 
genetic, epigenetic, metabolic and environmental factors cannot be replicated in constrained 
‘wet-lab’ experiments [33].  For example, in Figure 3 we schematized a normal state in which 
each component in the network is well-aligned and has normal functionality, and an abnormal 
state which is associated with misalignment within the network space but in which the 
components are (in isolation) within limits of functional normality.  Such a scenario could 
manifest as a changed ‘behaviour’ in a complex experimental system but elucidating this type 
of scenario is especially difficult.  It can only conceivably be achieved using future approaches 
dependent on more complex human-based systems (e.g. organ-on-a-chip models), in silico 
simulations and computer modelling that integrate an array of pre-clinical and clinical data.   
 Contemporary in silico simulations represent powerful adjunctive models for drug 
development that are reproducible and accurate.  However despite the accuracy of input 
parameters such models may yield outputs that may not be all that believable or physiologically 
relevant.  To this end, an appreciation of the ‘physiological gamut’, that considers variability and 
the operable range of biological processes under normal and diseased conditions [52, 53, 54] 
has permeated current thinking.  Most physiological processes exist with remarkably tight 
ranges (body temperature, pH, extracellular ion concentrations).  For example, systemic central 
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control of human body temperature [55]. involves a number of components whose function may 
fluctuate substantially but the ‘network’ physiological response is constrained to a normal value 
of approximately 37.5ºC.  Temperatures exceeding 40ºC are taken as a sign of high fever and 
those below 35 ºC hypothermic. Thus, the biologically relevant operable range of human body 
temperature that is compatible with a viable (i.e. living!) system is around 5ºC (± 2.5ºC; a gamut 
of 11% around the ‘normal’ value).  It is therefore appropriate to question whether incorporating 
data acquired from experimental systems at lower temperatures (e.g. room temperature (23ºC, 
32% outside of gamut) in computer simulations would provide misleading information rather 
than advance our mechanistic understandings [56].  Acutely aware of this problem, Windley 
and colleagues have recently proposed that data gathered at physiological temperatures 
should be used to constrain in silico models used for proarrhythmic risk prediction [57]. 
 It is already recognized that in silico models should not operate in out-of-gamut 
scenarios beyond the realms of physiological believability [58].  Conversely, there are 
arguments that data acquired in non-human animal models do not represent the full breadth of 
the ‘human gamut’.  For example, in-breeding has produced widely-used animal models of 
limited genetic diversity although there is strain-to-strain variation in phenotype [59, 60] and 
new resources exist to reconcile background genetic variation with biologic response [61]  
Moreover in animals, the underlying biology may occupy a different physiological space 
(different networks/systems) in which the mechanisms of regulation and control are distinctly 
different from those in human.  For example, mouse hearts beat much faster than human 
hearts (500-700 versus 50-70 bpm at rest), have different configuration of cellular ion pumps 
and exchangers for maintaining cellular ion fluxes during the cardiac cycle [62] and are 
resistant to ventricular fibrillation.  
 Approaches that incorporate the randomization of in silico parameters, non-linear 
modelling and chaos theory [63] together with the application of machine learning tools [64] and 
self-correcting parameterization [33] may lead to a better representation of ‘real world’ 
scenarios.  Drug development will also benefit from input data acquired from a broader palette 
of studies performed in humans e.g. new approaches to map to progression of sub-clinical 
cardiovascular disease [65, 66]. Factors that contribute to towards variability and mosaicism in 
in vitro platforms are being elucidated and may also help to explain why developing the next 
generation of drugs requires more than an understanding of the underlying biology [35, 67, 68, 
69, 70, 71, 72, 73]. 
 
Conclusions 
We are some way off fully being able to annotate, interrogate and quantify some of the most 
interesting aspects that underpin biological complexity. Clearly, understanding the strengths 
and limitations of in vitro and in vivo models in terms of their complexity and ability to 
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recapitulate key elements of a disease phenotype is essential to developing novel 
pharmacological therapeutics.  Werner Heisenberg is quoted as saying “….what we observe is 
not nature itself, but nature exposed to our method of questioning.” [74].  With regards to drug 
discovery efforts, selecting the most appropriate experimental models (which represent our 
“method of questioning”) and interrogating these models with the best available tools and 
relevant endpoints (how we expose and observe nature) is essential to discovering sorely 
needed novel therapeutics.  There is no one-size fits all solution; consideration of relevance 
and level of complexity in the context of selecting different models at different phases of the 
drug discovery process is essential as one proceeds from drug screening to drug testing in the 
ultimate and most relevant of complex systems, namely patients.  Complexity rules.    
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Figure Legends 
 
Figure 1. Horizontal and vertical network integration in quantitative and systems 
pharmacology.  
Horizontal integration is defined by Sorger and colleagues as the study of multiple receptors, 
signaling networks, metabolic pathways or cell types at the same time.  Vertical integration 
involves linking information together at multiple spatial and temporal scales and at different 
levels of biological complexity.  Figure is from [9] and is used under a CC-BY-SA3.0 licence.  
PK/PD, pharmacokinetics/pharmacodynamics. 
 
Figure 2. Complexity beyond signaling nodes at the cellular level. 
A cartoon scheme of the signaling events through which adrenaline (Adr) binding to the β-
adrenergic receptor (β-AR) results in the activation of physiological “fight-or-fight” mechanisms.  
The depiction of the β-AR activation cascade as a simplified linear ‘cause-and-effect’-type 
scheme though omits the complex regulation by feedback and feedforward events achieved by 
embedding this signaling node in a wider signaling context.  Interlocking processes that 
underpin cellular metabolism (green) and signaling (blue) illustrate the intricate linkage of 
biological components [75].  A detailed map of all of the components schematized here is 
available at http://biochemical-pathways.com/#/map 
Adr, adrenaline; AC, adenylate cyclase; Gα β γ, G-proteins; PKA, protein kinase A; reg, 
regulatory PKA subunit; cat, catalytic PKA subunit. 
 
Figure 3. Hierarchical network organization and perturbation. 
In this cartoon, network organization is given by the intrinsic modulation of excitation-
contraction coupling (ECC), the process by which electrical excitation of cardiac cells is 
transduced to the physical contraction of the myocardium [62].  Ca2+ release from intracellular 
sarcoplasmic reticulum stores (SR) is regulated by layered interaction with other processes of 
increasing complexity (e.g. metabolism, intercellular synchronization and subcellular 
ultrastructure).  Under normal conditions these regulated interactions are well-ordered but 
become disrupted in pathological states (disease) or when disrupted by toxic drugs.  This 
scheme also conceptualizes the idea that abnormal phenotypic states (i.e. disease or drug-
modified states) might be associated with the normal functional of individual processes but that 
they are misaligned relative to each other within the network space (or ‘gamut’ –see Section 4).  
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Figure 4. Mapping the trajectories of transitions between normal and abnormal states 
(A) Here we depict the increased perturbation of a system via the transition of a normal state 
into an abnormal state (N and A, respectively) that is associated with an intrinsic loss of 
complexity.  In the given scheme, progression between the start point (N) and end point (A) 
may occur via one of three different trajectories (orange, blue and red lines).  Perturbation in all 
three pathways is increased between times 1 and 2 (T1 and T2) and at each sampling point the 
extent of perturbation for orange, blue and red pathways is the same.  However the system 
complexity associated with each trajectory is reduced through different modalities where the 
rank order of complexity at both T1 and T2 is orange > blue > red.  
(B) A model in which the maladaptation of a biological system occurs via sequential transitions 
through dysfunctional homeostatic states of reduced complexity (‘pseudo-stable states’) 
precipitated by vertical crises has been proposed.[34, 51]  An expanded view of transitions 
through pseudo-stable states (i.e. a downward staircase) at T1 and T2 in each of the three 
trajectories shown in (A) is given.  The vertical points of transition may correspond to points of 
network fragility described by Verspignani [42].  The blue pathway is characterised by 
homogenous transitions between pseudo-stable states over the entire N-to-A transition. In 
contrast, the orange and red pathways proceed via heterogeneous transitions to reduced 
complexity states. 
 
Figure 5. Exploring complexity in a model of human cardiac cell signalling 
We illustrate the concepts described in Figure 4 using signals representing spontaneous Ca2+ 
oscillations in human cardiomyocytes exposed to drugs A and B and sampled at 5 times points 
(1-5).  Drugs A and B both elicit irregular beating and eventual cessation of calcium oscillations 
along with reductions in signal amplitude.  Sampling only at time point 5, it would be correct to 
conclude that drugs A and B produce the same phenotypic outcome (i.e. elimination of signal 
spikes).  However, more regular sampling would reveal that cells treated with drugs A and B 
exhibited comparable oscillatory behaviour at sampling times 1 and 2, which then had diverged 
by 3 and 4 only to re-converge on a common endpoint at 5.  Drugs A and B thus result in 
comparable outcomes (catastrophic perturbations in signalling) via different trajectories.  In (B), 
the differences in the signalling patterns of Ca2+ oscillation evoked by drugs A and B can be 
resolved using new methods for decoding cell signalling information [76, 77]. 
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Expert opinion (997 words). 
 
Calls for improved target-based screening and phenotypic screening to improve drug discovery 
and development are not new, nor are calls for more input from systems biology to assist in 
understanding the key elements in complexity that might be considered as mechanistic-based 
disease targets in the future.  The enabling technologies are becoming more sophisticated, but 
we must ask new questions of them whilst recognising their present limitations in a way that 
moves drug development forward.  Each approach must be applied at the proper time in the 
discovery/development pipeline (and with appropriate data) in order to provide holistic pre-
clinical assessments of drug safety and efficacy. Contextualization is key. For example, a 
generalized approximation of an organ's ‘physiologic state’ may be inferred from functional 
readouts, detailed information relating to cellular ultrastructural organization and tissue 
architecture and rich ‘omics’-level data (e.g. transcriptomic, genomic, proteomic and 
metabolomics).  However, at present, no single experimental model can provide these data in 
the correct context, at all levels of resolution and across all scales of complexity.  It would be 
expected though that in any chosen model system relevant component nodes and networks 
should exist (e.g. syncytial networks of stem-cell derived cardiomyocytes in vitro should 
possess functional β-AR signalling machinery (Figure 2), despite the (typical) lack of 
sympathetic innervation in culture).  Whether all of this information that emerges from different 
experimental models can be integrated holistically through ‘network inference’- based on the 
widely-held view that biological processes exist exclusively in ‘scale-free’ or ‘heavy-tailed’ 
networks consisting of multiple interconnected nodes- has been challenged by evidence that 
scale-free networks may not be all that prevalent in real-world scenarios [78, 79].   
 We have presented evidence that biological processes are complex on multiple 
horizontal and vertical levels of organization, and that popular target-centric approaches used 
in drug discovery efforts are incomplete in many aspects.  In addition, our understanding of 
even the simpler (cellular) levels of complexity is also often incomplete and inadequate.  Issues 
related to low throughput, and difficulties in properly interpreting results from more complex 
models hinders their use in early drug screening and efforts to replace simpler target-centeric 
screening.  Thus, despite continuing technological innovation, drug discovery efforts remain 
exceedingly difficult, time-consuming, and expensive.  In this article we have made the case 
that comprehensive drug screening requires a multi-scale approach encompassing all levels of 
complexity from reductionist investigations on single molecules to unequivocally resolve drug-
target interaction through to systems-level studies to interrogate ‘big data’ from populations of 
patients. We recognize that multi-faceted data almost always allows questions to be asked 
which the originators of the component datasets did not think to ask, perhaps because the 
requisite contextualisation (the “big picture”) was missing or that the full value of combining the 
Gintant & George 
Harnessing complexity in drug development 
	 23 
data with other datasets was not realised. Thus sharing good quality, structured datasets in 
searchable archives will be vital in allowing the events underpinning more complex 
biological scenarios to be properly synthesized. 
 None of this is all that disruptive; we have presented some actionable items which we 
consider to be a directed evolution rather than revolution.  A future challenge to drug discovery 
efforts is how best to blend the best output of systems biology approaches and experimental 
humanized models to guide discovery efforts.  This will entail greater communication between 
more traditional “wet lab” and “computational biologists” and informatics to enable/gain a better 
understanding of drug effects on normal and disease states.  From the present vantage point 
though, enthusiasm toward the improved power to crunch huge numbers should be tempered 
by an awareness that the outcomes may not be all that useful if we do not understand 
fundamental characteristics of the platforms that give rise to the numbers in the first place (“BIG 
DATA, little understanding).  We are optimistic that it is a matter of time until drug development 
emerges from a hinterland where “data rich” is often not very helpful, “stem cell” preparations 
are still evolving, and an appreciation of biology from a “network” perspective is still not very 
mainstream.  In order to help connect the data emerging from these evolving experimental 
models with computational modelling and forge new paths forward in understanding how 
complexity affects drug responses, the drug discovery process (and eventually, efficacy) will 
rely on enhanced use of informatics and applied statistics (e.g. mediation analysis [80]) which 
are absolutely necessary to untangle issues on inference and causality.  
 While efforts to adapt model systems continues, the pace of evolution though is 
probably too slow for some and drug hunters cannot wait.  Humanized integrated systems (in 
the form of human stem-cell derived preparations) offer an alternative to animal models with 
the potential benefit of providing more complex integrated systems that closely resembling 
human biology.  More recent work with such preparations have shown promise in modelling 
patient-specific diseases, with the cells (or engineered tissues) providing integration of signals.  
The extent to which such humanized systems (“proclinical studies”) replicate native responses 
will need to be constantly evaluated as these models evolve in engineered (and biological) 
complexity. It is worth emphasizing that by definition, no model is perfect, but some may be “fit 
for purpose”.  We would offer a note of caution also that the interpretation of outputs from 
humanized models needs to separate the ‘usability’ of the model from its usefulness. To this 
end, it is important that we make every effort to record and annotate as many aspects of the 
biology and phenotype as possible- especially those parameters that are more difficult to 
quantify but may unmask a new level of complexity and eventual understanding (e.g. the visible 
granularity of nuclei following exposure to drug).  We need to pre-empt retrospective mutterings 
of “if only we’d thought to record that at the time” wherever possible even though reconciling 
observation with underlying mechanism(s) remains a considerable challenge. 
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 Such demands will require a different type of scientific training and collaboration than is 
not demanded by typical reductionist approaches.  Perhaps a joint industry/governmental group 
could take up the challenge to guide such an educational initiative.  The industry, government 
regulators, and patients are waiting.  
 
 
Article highlights (182 words) 
 
- A lack of understanding of the complexity of biology in health and disease remains a 
key issue in limiting the discovery of novel pharmacologic therapeutics.  
- Systems-biology approaches and computational models provide alternative frameworks 
to test drugs (eventually beyond animal models). 
- Human stem cell-derived preparations represent an evolving experimental approach to 
interrogating drug efficacy and drug safety in the proclinical space (preclinical studies 
using human-derived “clinical-like” cells or tissues).  Further work is ongoing to define 
the minimum systems necessary to recapitulate the critical processes in healthy and 
diseased states (for safety and efficacy studies, respectively).  
- Experimental systems need to be configured and sampled in ways such that data 
output reflects the dynamic (temporal) changes underpinning disease-linked or drug-
toxicity evoked phenotypes. 
- The integration of multiple network- and systems-based responses should provide 
better and more comprehensive assessments of drug effects compared to more 
traditional target-centric approaches to drug discovery. 
- Phenotypic screening using human stem cell-derived cells and tissues represent a 
complementary approach to quantitative systems biology-based studies that include 
higher levels of integration and complexity for evaluating drug candidates.   
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